華北製藥(600812.SH)：重組事項獲控股股東批覆
格隆匯 7 月 8日丨華北製藥(600812.SH)公佈，公司於2020年7月8日收到控股股東冀中能源集團有限責任公司(“冀中能源集團”)出具的《關於華北製藥股份有限公司發行股份及支付現金購買資產並募集配套資金暨關聯交易的批覆》(冀中能源財字【2020】39號)。冀中能源集團作為國家出資企業，按照國務院國有資產監督管理委員會、中華人民共和國財政部、中國證券監督管理委員會聯合發佈的《上市公司國有股權監督管理辦法》(國資委、財政部、證監會令第36號)的相關規定，對公司發行股份及支付現金購買資產並募集配套資金暨關聯交易相關事項批覆如下：
一、同意公司發行股份及支付現金購買資產並募集配套資金暨關聯交易方案。
二、同意華藥集團將其持有的華北製藥集團愛諾有限公司(“愛諾公司”)51%股權、華北製藥集團動物保健品有限責任公司(“動保公司”)100%股權及華藥集團持有的華北牌系列商標資產(上述三項資產以下合稱“標的資產”)出售給公司。
三、同意公司以發行股份及支付現金的方式購買華藥集團持有的標的資產並募集配套資金。標的資產的交易價格合計(不含華北牌系列商標資產交易增值税)為人民幣約8.86億元，其中，愛諾公司51%股權的交易價格為人民幣約1.52億元；動保公司100%股權的交易價格為人民幣7450.39萬元；華北牌系列商標的交易價格(不含增值税)為人民幣約6.6億元。華藥集團持有的愛諾公司51%股權與動保公司100%股權全部通過發行股份支付對價；華藥集團持有的華北牌系列商標資產通過發行股份支付對價人民幣約3.9億元，通過現金支付對價人民幣2.7億元。公司用於支付股份對價所發行股份的發行價格為人民幣7.28元/股。
四、同意公司向不超過35名(含35名)符合條件的特定投資者非公開發行股份募集配套資金，募集資金總額不超過人民幣5.5億元，發行價格遵照《上市公司證券發行管理辦法》相關規定執行。
五、同意華藥集團與公司就本次交易簽署的相關協議。
六、同意公司將本次交易相關事項提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
